OVER DEZE AFLEVERING
bioAffinity Technologies CEO Maria Zennes joined Steve Darling from Proactive to discuss the company's noninvasive lung cancer detection technology, reported 200% year-over-year growth in the second quarter, insurance reimbursement and plans to expand its diagnostic platform into chronic obstructive pulmonary disease (COPD) and asthma.
Zannes explained that bioAffinity Technologies has developed a diagnostic platform designed to analyse the lung microenvironment and identify signs of disease. Its initial commercial application focuses on lung cancer through a noninvasive test that uses sputum samples collected by patients at home.
The samples are analysed using flow cytometry and an artificial intelligence-based algorithm to help determine whether lung cancer is present.
The test is prescribed by physicians for patients who may have suspicious lung nodules. According to Zannes, the technology can provide additional information to help physicians assess patients and make decisions about further diagnostic procedures or continued monitoring.
On the commercial side, Zannes reported 200% year-over-year growth in the second quarter and said the company was also experiencing year-over-year growth in the third quarter. She highlighted Medicare reimbursement and coverage by most private insurers as important factors supporting the adoption of its diagnostic technology.
The company is also exploring opportunities to expand the platform beyond lung cancer. Its development plans include applications in COPD and asthma, where the technology could support precision medicine by helping physicians better characterize lung inflammation and identify patients who may benefit from specific treatments.
She also discussed collaborations with AB Medical, which has distribution connections in the Veterans Administration market, and Pictor, a technology partner supporting the development of additional diagnostic capabilities. The Pictor collaboration is expected to contribute molecular and proteomic analysis alongside bioAffinity's existing flow cytometry platform.
#proactiveinvestors #bioaffinitytechnologies #nasdaq #biafw #MariaZannes #CHEST2026 #LungHealth #Asthma #COPD #PrecisionMedicine #Biomarkers #ArtificialIntelligence #Diagnostics #LungInflammation #CyPathLung #Biotechnology
Zannes explained that bioAffinity Technologies has developed a diagnostic platform designed to analyse the lung microenvironment and identify signs of disease. Its initial commercial application focuses on lung cancer through a noninvasive test that uses sputum samples collected by patients at home.
The samples are analysed using flow cytometry and an artificial intelligence-based algorithm to help determine whether lung cancer is present.
The test is prescribed by physicians for patients who may have suspicious lung nodules. According to Zannes, the technology can provide additional information to help physicians assess patients and make decisions about further diagnostic procedures or continued monitoring.
On the commercial side, Zannes reported 200% year-over-year growth in the second quarter and said the company was also experiencing year-over-year growth in the third quarter. She highlighted Medicare reimbursement and coverage by most private insurers as important factors supporting the adoption of its diagnostic technology.
The company is also exploring opportunities to expand the platform beyond lung cancer. Its development plans include applications in COPD and asthma, where the technology could support precision medicine by helping physicians better characterize lung inflammation and identify patients who may benefit from specific treatments.
She also discussed collaborations with AB Medical, which has distribution connections in the Veterans Administration market, and Pictor, a technology partner supporting the development of additional diagnostic capabilities. The Pictor collaboration is expected to contribute molecular and proteomic analysis alongside bioAffinity's existing flow cytometry platform.
#proactiveinvestors #bioaffinitytechnologies #nasdaq #biafw #MariaZannes #CHEST2026 #LungHealth #Asthma #COPD #PrecisionMedicine #Biomarkers #ArtificialIntelligence #Diagnostics #LungInflammation #CyPathLung #Biotechnology
Engels
Verenigde Staten
TRANSCRIPTIE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
OUDE AFLEVERINGEN ZOEKEN
Zoek naar eerdere afleveringen van Proactive - Interviews for investors.
ANDERE AFLEVERINGEN IN DEZE PODCAST
Blockmate Ventures Chairman Domenic Carosa joined Steve Darling from Proactive to announce that the company has entered into a binding agreement with Scannit Inc. to acquire its first NVIDIA B200 AI compute node, marking its entry into the AI neocloud and GPU computing market.
Under the agreement …
Great Red Lake Gold Corp Chief Financial Officer Brian Morales joined Steve Darling from Proactive to discuss the company's move into copper exploration, its acquisition of the Bilton-Brown property in Ontario and plans to advance the project toward a potential drilling program in 2027.
Morales ex…
Foresight Environmental Infrastructure (LSE:FGEN) investment manager Ed Mountney spoke with Proactive's Stephen Gunnion about the company’s £104 million sale of its remaining 49% stake in six anaerobic digestion plants, debt reduction and plans to reinvest in environmental infrastructure.
Mountney…
Empire Metals (AIM: EEE, ASX: EEE) managing director Shaun Bunn spoke with Proactive's Stephen Gunnion about progress towards pilot-scale testing at its Pitfield Titanium Project in Western Australia, plans to produce high-purity titanium dioxide and the next steps towards development.
Bunn explai…
Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van Proactive, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.
BEWERKEN
Bedankt voor uw hulp bij het up-to-date te houden van de podcast-database .
